Targeted therapy for liver cancer: updated review in 2012
M Kudo - Current Cancer Drug Targets, 2012 - ingentaconnect.com
In May 2007, sorafenib (Nexavar®) was approved for “unresectable hepatocellular
carcinoma (HCC)”, and was the first molecular targeted agent for use in HCC. To date …
carcinoma (HCC)”, and was the first molecular targeted agent for use in HCC. To date …
[引用][C] Targeted Therapy for Liver Cancer: Updated Review in 2012
M Kudo - Current Cancer Drug Targets, 2012 - cir.nii.ac.jp
Targeted Therapy for Liver Cancer: Updated Review in 2012 | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
Targeted therapy for liver cancer: updated review in 2012
M Kudo - Current cancer drug targets, 2012 - pubmed.ncbi.nlm.nih.gov
In May 2007, sorafenib (Nexavar ) was approved for" unresectable hepatocellular
carcinoma (HCC)", and was the first molecular targeted agent for use in HCC. To date …
carcinoma (HCC)", and was the first molecular targeted agent for use in HCC. To date …
Targeted therapy for liver cancer: updated review in 2012.
M Kudo - Current Cancer Drug Targets, 2012 - europepmc.org
In May 2007, sorafenib (Nexavar ) was approved for" unresectable hepatocellular
carcinoma (HCC)", and was the first molecular targeted agent for use in HCC. To date …
carcinoma (HCC)", and was the first molecular targeted agent for use in HCC. To date …
[引用][C] Targeted therapy for liver cancer: updated review in 2012
M KUDO - Curr Cancer Drug Targets, 2012 - cir.nii.ac.jp